CytoDyn announces results from preclinical studies with SMC

CytoDyn (CYDY) announced positive results from its preclinical studies with SMC Laboratories, SMC. The three studies demonstrated statistically significant reversal of liver fibrosis with leronlimab monotherapy. The first two studies, completed in late 2024, evaluated leronlimab in the STAM model of metabolic dysfunction associated steatohepatitis, MASH, with fibrosis in mice who received a single dose of Streptozocin at birth and were then fed a high fat diet from weeks four to twelve. The third study, concluded in January 2025, evaluated reversal of liver fibrosis in mice who received carbon tetrachloride, a liver fibrosis-inducing agent, from birth to sacrifice at day 35.